Usability Testing for Mechanical Cervical Dilatation. For #Gynecologists #NPs #PAs Please take the test! https://lnkd.in/dhawS_8s
Amarastesia LTD
Krankenhäuser und Gesundheitseinrichtungen
Courroux, Jura 161 Follower:innen
Putting patients at the center of our business we innovate groundbreaking solutions that increase safety & efficiency
Info
We develop innovative medical solutions that enhance patients safety being atraumatic and minimally invasive.
- Website
-
www.amarastesia.com
Externer Link zu Amarastesia LTD
- Branche
- Krankenhäuser und Gesundheitseinrichtungen
- Größe
- 2–10 Beschäftigte
- Hauptsitz
- Courroux, Jura
- Art
- Einzelunternehmen (Gewerbe, Freiberufler etc.)
- Gegründet
- 2024
- Spezialgebiete
- cosmetic injections, Non Surgical Facelift, lip augmentation, Fat Transfer und Platelet Rich Plasma
Orte
-
Primär
Wegbeschreibung
Courroux, Jura 2822, CH
Beschäftigte von Amarastesia LTD
Updates
-
Exciting times at the Medtech Congress at Basel Innovation Park. Connecting with local SMEs, staying updated on the latest medtech trends, and growing as a startup and entrepreneur are invaluable experiences. They not only bolster your network but also provide real-world insights that can drive your success.
-
Research conducted by NYS SCIENCE & TECHNOLOGY LAW CENTER, concluded that none of the active patents in the USA have features affecting the Freedom to Operate of cerA&Mvix. https://lnkd.in/dsXzETqi
cerA&Mvix obtains FREEDOM TO OPERATE, 08/2024
amarastesia.com
-
Another graduation, another milestone reached another incredible experience for Amarastesia and our team. We inspire confidence! The jury concluded and so it is. Based on real data, cerA&Mvix will inspire confidence to providers, patients and judges! We are determined to make the surgical world Safe and Easy to navigate!
-
-
Insightful. We pioneer patient centric medical solutions and devices. CerA&Mvix a game changer in surgical instrumentation introduces for the 1st time the concept of a Safe Passageway for Instruments. We recognize access to care is still a benefit of a few, therefore we launched a self-administrable drug delivery system with remote Practitioner guidance.
Switzerland’s #biotech sector is experiencing unprecedented momentum, as industry leaders continue to make strategic moves that solidify their standing in the global market. This week’s updates underscore the sector’s strength, driven by cutting-edge innovation, substantial funding rounds, and deepening international collaborations. Here’s our overview of this week's highlights: MoonLake Immunotherapeutics (NASDAQ: MLTX) raised CHF 415M in follow-on financing to accelerate treatments for inflammatory diseases. Alentis Therapeutics secured CHF 105M to advance its cutting-edge research in oncology and fibrosis, cementing its leadership in these critical areas. Noema Pharma continues its mission to address neurological diseases, raising CHF 103M in Series B funding to expand its clinical pipeline. Rejuveron Vascular Therapeutics AG raised CHF 75M in Series B funding, focused on healthy aging and regenerative medicine, an area gaining increasing global attention. CRISPR Therapeutics and Vertex Pharmaceuticals push forward with gene-editing technologies for sickle cell disease, showcasing the power of collaboration in precision medicine. Oculis successfully raised USD 144M via a SPAC deal on NASDAQ, furthering its innovative solutions in ophthalmology. Santhera Pharmaceuticals finalized a CHF 1B acquisition deal with Ironwood Pharma, signaling increased consolidation and focus on neuromuscular and respiratory disease treatments. 🌟 Swiss Startup Spotlight: Amarastesia LTD is pioneering new methods in skin regeneration, leveraging Switzerland’s innovation ecosystem to develop breakthrough therapies. Altiscreen is making waves with its early-stage cancer detection technologies, addressing a critical gap in global healthcare. With CHF 2B+ raised this year and a series of high-impact acquisitions and IPOs, Swiss biotech is poised for continued growth. As we look ahead to 2025, expect these companies to drive innovation and reshape the future of healthcare. 💡 Are you a biotech startup looking to scale? Let’s discuss how Vias Digital can help accelerate your growth with regulatory-compliant, data-driven marketing and communications strategies. #MarketingStrategy #HealthcareInnovation #Marketing #DigitalMarketing #Communications
-
Amarastesia and CerA&Mvix, a game changer in atraumatic cervical canal instrumentation and Safe Pass-through for instruments have reached incredible Milestones: 1. Functional prototype 2. FDA presubmission meeting 3. Strong partnerships with International Academic Centers. Many thanks to Dr. Kurian Thott for his leadership, support and excellence in R&D.
-
Amarastesia LTD hat dies direkt geteilt
We courteously welcome you to be an honorable keynote speaker for the “8th World Congress on Gynecology and Obstetrics" which is going to be held from August 31 to September 2, 2023, in London, UK. Title: Disposable, pass-through cervical dilator: a new approach for cervical dilatation It is a great pleasure to have you at the conference as a valuable "Dr. Roxana Belciu Kerns" whose expertise will make a difference among the attendees. Join Now Register your slot: https://lnkd.in/eVJpp85p For more information click here: https://lnkd.in/ec_BCrZg Whatsapp No. : +44 7537 133377 Contact Mail: wcgo@pulsusgathering.org #gynecology #obstetrics #infertility #reproductivehealth #london
-
-
Amarastesia LTD hat dies direkt geteilt
Let's make Women's Health a Priority! There are more than 80 million Hysteroscopies each year and at least 30% get complications due to mechanical instrumentation of the cervical canal. Atraumatic cervical canal dilation is a must! https://lnkd.in/gPWrgb4U
-